Citations

Clear

4799 citation(s) found for "Ro, Jennifer".

Differential associations of individual- and neighborhood-level socioeconomic status with mortality in dementia: Findings from the Mayo Clinic Study of Aging
Lin, Jie , Vassilaki, Maria , Sauver, Jennifer St., Petersen, Ronald C., Wi, Chung Il, Juhn, Young J., Sham, Yuk , Sohn, Sunghwan , St Sauver, Jennifer, Sham, Yuk , Sauver, Jennifer L. St. , Petersen, Ronald C. , Wi, Chung‐Il , Juhn, Young J. , Chen, Jun

Mayo Clinic

Journal of Alzheimer’s Disease | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13872877261482043 | PMID 42690834 Get It

Background Alzheimer's disease (AD) and related dementias are leading causes of death worldwide. While socioeconomic status (SES) is a critical determinant, its impact on mortality after diagnosis remains understudied. Objective To investigate the roles of neighborhood-level and individual-level SES in predicting mortality risk among older adults with incident dementia. Methods We analyzed data from 924 participants with incident dementia from the Mayo Clinic Study of Aging (N = 6909), a cohort with clinical follow-up visits every 15 months. We assessed mortality risk using Cox's time-varying survival regression, adjusting for time-fixed and time-varying covariates. Primary predictors were neighborhood-level SES (Area Deprivation Index [ADI]) and individual-level SES (housing-based SES index [HOUSES], education, and occupation). We also applied a random survival forest model to assess the predictive contribution of SES indicators and identify influential predictors. Results 857 participants (92.7%) died, with a median time from dementia diagnosis to death of 29 months (IQR: 12–54). Lower SES measured by HOUSES was associated with increased mortality risk (HR 1.28, 95% CI 1.07–1.52). Conversely, ADI, education, and occupation were not associated with mortality. Male sex, older age, congestive heart failure and diabetes were associated with higher mortality risk. In predictive analysis, HOUSES ranked among the top 10 contributors to mortality risk. Conclusions Among older adults with dementia, lower HOUSES was associated with higher mortality risk beyond neighborhood-level deprivation, education, and occupation. Integrating this housing-based individual-level SES measure into dementia care planning may help identify patients with greater socioeconomic vulnerability and inform mortality risk stratification.
Hematology Oncology Social Work Quality Improvement Initiative: The Critical Role of Timely Social Work Support in Patient-Centered Cancer Care: A Responsive Practical Proactive Approach (RPP)
Gustetic, Elaine, Markowitz, OSW-C LCSW Jennifer, Graham, J. R. , Johnson, CMA Emaline, Alaimo, RCSWI MSW Valentina, Dolan, LCSW Karrie, Ciccone, Barbara Lubrano di, Graham, LCSW Jennifer

Mayo Clinic

No container title available | August 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10348566/v1 Get It

Abstract Purpose The devastation and impact of a new cancer diagnosis can be compounded by psychosocial challenges that can significantly affect patient outcomes. Historically at Mayo Clinic Florida, social work contact with newly diagnosed hematology oncology patients occurred at various and inconsistent times during treatment. Baseline data revealed that 2.16% of these patients received social work contact ranging from 2 to 43 days after diagnosis. Referrals were typically initiated following elevated distress screening or provider-identified needs. This quality improvement initiative explored the impact of embedding early clinical social work services to increase timely social work support for patients and awareness of the role of social work and resources. Methods All patients newly diagnosed with hematological malignancy were scheduled for first contact with social work within two weeks of meeting with their medical provider. During the first social work appointment, psychosocial screening was performed and social work role and resource education was provided. A follow-up consultation was scheduled if needs were identified. Results 96 out of 122 (78.6%) newly diagnosed patients had social work contact for an initial screen during this quality improvement project. There was a 76.44% increase from baseline in the number of patients receiving social work support as a result of this initiative. 52.08% of the newly diagnosed patients proceeded from this initial screening to a scheduled social worker consult. Conclusion Early and proactive social work outreach through a Responsive Practical Proactive (RPP) approach improved access to psychosocial care and helped address gaps between distress screening and timely intervention.
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia
Noll, Julia Han , Dersh, Devin , Li, Jiang Yuan, Hemani, Humza , Lavorando, Maya, Bartoszek, Robert, Amses, Kevin R. , Jain, Ankita , Minehart, Janna , Shestov, Max A, Camerini, Elena , Loren, Alison W., Woyach, Jennifer A. , Goronzy, Jorg Josef, Kater, Arnon P. , Porter, David L., Bushman, Frederic D, Levine, Bruce L. , June, Carl H. , Long, Meixiao, Weng, Nan‐ping , Diorio, Caroline, Ramirez-Fernandez, Angel , Paruzzo, Luca , Camerini, Elena , Peters, Fleur S , Huang, Xiao , Woyach, Jennifer A , Kater, Arnon P , Ruella, Marco , Byrd, John C , Schuster, Stephen J , Siegel, Donald L , Levine, Bruce L , June, Carl H , Frey, Noelle V , Cohen, Adam D , Garfall, Alfred L , Long, Meixiao , Maus, Marcela V , Weng, Nan-Ping , Fraietta, Joseph A , Bartoszek, Robert L. , Ho, Matthew , Paruzzo, Luca , Shestov, Max, Loren, Alison W. , Goronzy, Jörg J. , Ruella, Marco , Byrd, John C. , Powell, Daniel J. , Gill, Saar , Porter, David L. , Schuster, Stephen J. , Bushman, Frederic D. , Frey, Noelle V. , Cohen, Adam D. , Garfall, Alfred L. , Diorio, Caroline J.

Mayo Clinic

Blood Journal | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025032274 | PMID 42636161 Get It

CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional CLL T-cells retain inflammatory cytokine production. We tested whether this paradox reflects immunosenescence, an aging-like program defined by costimulatory loss, DNA damage, inflammatory secretion, repertoire restriction, and proliferative arrest. In response-linked preinfusion CTL019 products, nonresponders and short partial responders had higher senescence and senescence-associated secretory phenotype (SASP) programs than the functional-responder group, comprising complete responders and partial responders with transformed disease. These programs were detectable before infusion and became more prominent during manufacture in susceptible products. They tracked with weak in vivo CAR T-cell expansion and were associated with inferior survival. Serum proteomics revealed a circulating, CLL-associated SASP-like inflammatory milieu in nonresponders. Flow cytometry and T-cell receptor (TCR) profiling showed that poor responders carried CD27⁻CD28⁻ and KLRG1⁺ CD8 T-cells at apheresis, lower product CD27, and reduced product TCR diversity. Research-manufactured CAR T-cells from treatment-naïve CLL samples displayed the same state, most prominently in CD4 CAR T-cells, with SA-β-gal, p16, p53, DNA damage, depletion of less-differentiated states, and senescence-enriched transcriptomes. Under repeated CD19 stimulation, CLL-derived products reached a proliferative ceiling, and p53-high products lost cytotoxic reserve. Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model. Together, these data identify immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in CLL and a candidate for therapeutic modulation.
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome
Kaufman, Richard M., Hoen, Anne G., Khan, Jenna, Knudson, C. Michael, Romero, Andres E. Mindiola, Mo, Allison , Takanashi, Minoko , Collaborative, UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST), Cardigan, Rebecca, Stanworth, Simon J., Commins, Scott P. , Scherer, Emily A., Davenport, Robertson D., Afraz, Sajjad, Andrews, Jennifer , Casey, John, Sullivan, Jensyn Cone , Cousins, Clara C. , Giorgi, Valeria De , Delaney, Meghan, DelBaugh, Regina M. , Gilstad, Colleen W. , Gofton, Alexander , Hill, Kate, Hogan, Keenan , Humbrecht, Catherine , Ikeda, Kazuhiko, Javanbakht, Ayda, Juskewitch, Justin E, Wojtowicz, Monique M. Menzies, Miller, Maureen J., Mills, Georgia, Nelson, Anna C. , Pauly, Marie C., Poisson, Jessica , Raval, Jay S., Samy, Nikitha, Sato, Tomohiko, Takeda, Yoshinori , Thibodeaux, Suzanne R. , Nunen, Sheryl van, Virk, Mrigender S., West-Mitchell, Kamille, Yamanouchi, Jun, Yoshihara, Satoshi, Zheng, X. Long, Ziman, Alyssa, Cone Sullivan, Jensyn , Kaufman, Richard Max , Hoen, Anne Gatewood , Knudson, Charles Michael , Metcalf, Ryan A. , Schäfer, Richard , Dunbar, Nancy M. , Cardigan, Rebecca A. , Stanworth, Simon J., Scherer, Emily A. , Cervinski, Mark A , Arai, Yasuyuki , Brugnara, Carlo , Allen, Elizabeth S. , Aurich, Konstanze , Casey, John , Cohn, Claudia S. , Crowe, Elizabeth P , Delaney, Meghan , Hendrickson, Jeanne E. , Hill, Kate, Ikeda, Kazuhiko , Jacquot, Cyril , Javanbakht, Ayda , Juskewitch, Justin E. , Lu, Wen , Wojtowicz, Monique Menzies , Miller, Maureen J. , Nelson, Anna , Pagano, Monica B. , Pauly, Marie-Christin , Saifee, Nabiha H , Sato, Tomohiko, Takeda, Yoshinori, Tiberghien, Pierre , Nunen, Sheryl van, Virk, Mrigender , Wood, Erica M , Yoshihara, Satoshi , Zheng, X. Long, Ziman, Alyssa

Mayo Clinic

JAMA Internal Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.3983 | PMID 42636004 Get It

Importance Recent case reports suggest that B antigen–containing blood products may be associated with anaphylactic transfusion reactions in recipients with preformed immunoglobulin E to galactose- α -1,3-galactose (alpha-gal). Objective To test the association of local alpha-gal syndrome (AGS) prevalence and allergic transfusion reaction (ATR) in patients with blood type O. Design, Setting, and Participants In this international, multicenter, retrospective cohort study at academic medical centers, sites were assigned to AGS high- or low-prevalence clusters based on the known geographic distribution of AGS. Data were collected on platelet or plasma transfusions and ATRs during 2020 to 2024. Consecutive patients receiving platelet or plasma transfusions were included. Exposures Patients with blood type O who received B or AB units and patients with blood type O who received O units (reference group) in AGS high- and low-prevalence clusters were compared. Main Outcomes and Measures Before data collection, the hypothesis was that if transfusion-related alpha-gal syndrome (TRAGS) is a true clinical entity, excess ATRs to group B or AB units would be detected in AGS high-prevalence regions exclusively. The main measure was the overall risk ratio (RR) for ATRs to B or AB plasma or platelets in AGS high- vs low-prevalence clusters. Results In total, 558 823 platelet and plasma transfusions at 40 sites in 5 countries were analyzed, of which ATRs occurred in 1744 transfusions (0.3%). In the US AGS high-prevalence cluster (9 sites), significantly more ATRs of any severity occurred among patients with blood type O who received B or AB units vs patients with blood type O who received O units (overall RR, 3.93; 95% CI, 2.96-5.21; P < .001). In contrast, in the primary analysis of the AGS low-prevalence cluster (15 sites), excess ATRs to B or AB units were not detected. In subgroup analyses among patients with blood type O receiving B units, the RR for moderate to severe ATRs was 9.14 (95% CI, 5.39-15.52; P < .001) in the AGS high-prevalence cluster vs 2.15 (95% CI, 1.34-3.47; P = .002) in the AGS low-prevalence cluster. Outside the US, a signal consistent with TRAGS was not detected. Conclusions and Relevance This cohort study provides provocative epidemiologic evidence that TRAGS may be a unique manifestation of AGS and a previously unrecognized risk associated with transfusion. In AGS high-prevalence regions, blood collectors and hospital transfusion services should consider approaches to preventing severe ATRs from B or AB plasma or platelet units.
Inhibition of EED Enhances osteogenic differentiation and Bone Formation: A Potential Therapeutic Strategy for Osteogenesis Imperfecta
Jeldres, Margarita E Carrasco , Pichurin, Oksana , Weaver, Samantha , Cheang, Eric , Tokach, Leah E. , Westendorf, Jennifer J. , Deyle, David R. , Carrasco Jeldres, Margarita E , Weaver, Samantha R , Westendorf, Jennifer J

Mayo Clinic

JBMR Plus | August 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jbmrpl/ziag142 | PMID 42708099 Get It

Abstract Osteogenesis imperfecta (OI) is a heterogeneous group of inherited connective tissue disorders primarily caused by dominant mutations in COL1A1 or COL1A2 that impair type I procollagen folding and secretion. Misfolded collagen accumulates in the endoplasmic reticulum (ER), triggering ER stress and osteoblast dysfunction and bone fragility. Current pharmacologic therapy focuses on inhibiting bone resorption but has limited efficacy and does not address the underlying biology of the disease. The epigenetic regulator Polycomb-repressive complex 2 (PRC2) has emerged as an important regulator of bone formation. Genetic and pharmacologic disruption of PRC2 enhanced osteogenic differentiation in wild-type cells. Here we demonstrate that inhibition of the PRC2 through targeting its essential component embryonic ectoderm development (EED) enhances osteogenic differentiation, improves bone architecture in male Col1a2+/G610C OI mouse models, modulates the integrated stress response (ISR), and improves ER morphology in OI cells. These findings identify EED inhibition as a novel epigenetic strategy to restore collagen homeostasis and improve skeletal integrity in OI.
OA07.2. Baseline Mucosal Impedance on High-Resolution Impedance Manometry Distinguishes Active From Inactive Eosinophilic Esophagitis
Martinez, Josealberto Arenas, Freeman, Catherine, Crowell, Michael, Vela, Marcelo, Wright, Benjamin, Horsley-Silva, Jennifer, Wang, Fangfang, Arenas-Martínez, Josealberto S., Freeman, Catherine , Crowell, Michael D. , Vela, Marcelo F. , Horsley‐Silva, Jennifer L.

Mayo Clinic

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.050 Get It

Abstract Topic Benign Disease: Eosinophilic Esophagitis Background Active inflammation in eosinophilic esophagitis (EoE) disrupts the mucosal barrier, leading to dilated intercellular spaces and decreased transepithelial electrical resistance. Mucosal impedance (MI) has been used to assess mucosal integrity in EoE. We evaluated whether baseline MI measured by high-resolution impedance manometry (HRIM) distinguishes active and inactive EoE. Methods We retrospectively reviewed data from patients with EoE who underwent endoscopic esophageal biopsies within three months of HRIM from 2018-2026 at our tertiary referral center and had no treatment changes between studies. We excluded patients with a history of foregut surgery, erosive esophagitis, or Barrett’s esophagus. Demographics, endoscopy and pathology results were collected by chart review. Active EoE was histologically defined as ≥15 eosinophils per high-power field. Esophageal baseline MI was measured in the 30-second landmark period for the whole esophagus (from 2 cm above LES to 2 cm below UES), distal esophagus (from 2–7 cm above LES), and mid/proximal esophagus (from 10 cm above LES to 2 cm below UES). Mann–Whitney U or T tests were used for comparisons . Optimal MI thresholds were identified by Youden index with 10,000 bootstrap validations, and interrater reliability was assessed using two-way mixed effects intraclass correlation coefficients. Results Seventy-three patients were included: 37 (51%) female, median age 52 years, median BMI 27.2 kg/m2. Fifty-seven patients (78%) had atopic history, including seasonal allergies (38, 52%), asthma (31, 42%), eczema (21, 29%), and food allergies (19, 26%). Thirty-nine patients (53%) were receiving proton pump inhibitors, 25 (34%) were not on EoE therapy, 5 (6.8%) were on swallowed topical steroids, 3 (4.1%) were on dupilumab, and 1 (1.4%) was on an elimination diet. Esophageal strictures were present in 23 patients (32%), and 45 (62%) had active EoE. Baseline MI measurement showed high interrater reliability (n=50, 2 raters; intraclass correlation coefficient 0.937–0.963, p<0.001). Basal mean and minimal impedance were significantly lower in active EoE across all segments, greatest in the distal esophagus (all p<0.05; Figure 1). ROC analysis showed high discrimination of distal mean MI, with a cutoff ≤1.91 kΩ (AUC=0.837, sensitivity 67.9%, specificity 86.7%, Youden 0.545; Figure 2). Conclusion Baseline mucosal impedance during HRIM distinguishes active from inactive EoE, with strongest discrimination in the distal esophagus, supporting MI as a potential, minimally-invasive physiologic marker of mucosal inflammation and disease activity. Clinically, MI may serve as an adjunct tool in dysphagia evaluation, prompting EoE-directed biopsy when abnormal, aiding management in biopsy–symptom discordance, and potentially supporting disease monitoring in selected patients. Larger prospective studies are warranted.
OA07.1. Clinical Features and Treatment Outcomes in Esophageal Lichen Planus: A Retrospective Multicenter Cohort Study
Wilder, Evan, Mann, Russaal, Keswani, Shiwani, Martinez, Josealberto Arenas, Codipilly, Chamil, Eluri, Swathi , Vela, Marcelo, Ramirez, Francisco, Horsley-Silva, Jennifer, Iyer, P. K. R., Arenas-Martínez, Josealberto S., Codipilly, Don C. , Vela, Marcelo F. , Kahn, Allon , Horsley‐Silva, Jennifer L. , Iyer, Prasad

Mayo Clinic

Diseases of the Esophagus | August 22, 2026 | Volume: 39 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doag077.049 Get It

Abstract Topic Benign Disease: Other Background Lichen planus is a chronic immune-mediated skin disease that may involve the esophagus. Esophageal lichen planus (ELP) is considered rare, but likely underdiagnosed. Lack of published guidelines for ELP results in significant treatment variability. Given heterogeneous practice patterns and emerging treatments, further outcome data are needed. Methods A retrospective cohort of ELP patients was assembled from 3 academic centers. Patients ≥ 18 years old were identified by ICD10 code search (L43.8) in the electronic health record, from 2006 to 2025. Patients were included if they had initial endoscopy, histology, and follow-up endoscopy showing features of LP, and excluded if there was diagnostic uncertainty, unavailable procedural documentation, or other esophageal diseases. Endoscopic findings were assessed qualitatively by manual review of reports. Data abstracted included demographics, presenting symptoms, endoscopic/histologic findings, treatment, and clinical outcomes. Statistical analysis was performed in R. Results 193 patients met inclusion criteria. Mean age at index endoscopy was 65 years, 86% were female, 98% were non-Hispanic Caucasian, 39% were ever smokers, and mean BMI was 26. Dysphagia was the most common presenting symptom (90%). Strictures were common (73%), 58% underwent dilation during initial endoscopy. Endoscopic findings included presence of sloughing (20%), exudate (22%) and friability (23%). Histology showed lymphocytic infiltrate (47%), parakeratosis/dyskeratosis (42%) and Civatte bodies (17%). Topical steroids (71%) and PPIs (63%) were used most frequently for treatment. Immunosuppressives (tacrolimus, systemic steroids, mycophenolate, methotrexate, hydroxychloroquine, cyclosporine, azathioprine, JAK inhibitor) were used in 54% of patients. Endoscopic improvement was seen in 66%, with highest response rates in tacrolimus (100%), hydroxychloroquine (100%), and a JAK inhibitor (100%). Symptom improvement was seen in 63%, with the greatest benefit seen in patients treated with a JAK inhibitor (100%) and hydroxychloroquine (86%). Conclusion In this large, multisite cohort, ELP demonstrated significant morbidity, with high rates of dysphagia, strictures, and inflammatory changes. Dilation appeared to be safe, with only a single iatrogenic perforation identified. Esophageal squamous cell cancer risk was low but present, at 4%. Despite heterogeneous treatment practices, several therapies – tacrolimus, hydroxychloroquine, and JAK inhibitors – were associated with marked endoscopic and symptomatic improvement. Prospective studies are needed to clarify the optimal approach to pharmacological management of ELP.
Expert consensus recommendations on appropriate treatment for telogen effluvium
Middleton, Hayden T. , Monahan, Erin, James, G, Franley, Brittney, Chavez, Magdalena, Kwong, Danny, Pham, Van, Griffith, Cynthia F. , Whinery, Sarah Jane, Blank, Alexander , Lightowler, Jennifer, Sledge, Eva, Griffith, Cynthia Faires , Link, Jenny

Mayo Clinic

Journal of Dermatology for Physician Assistants | August 21, 2026 | Volume: 20 | Issue: 3 | Pages: 8-13

10.1097/jdpa.0000000000000114 Get It

Background: Telogen effluvium (TE) is one of the most common forms of nonscarring alopecia. TE typically presents as sudden diffuse shedding of hair, and generally occurs 3–4 months after a triggering event such as physiological or psychological stress, certain medications, or hormonal changes. Despite the high prevalence of TE, no standardized clinical guidelines for the management of this condition currently exist. Objective: To address the lack of standard clinical guidelines for the management of TE, a multidisciplinary panel of dermatologists, dermatology advanced practice providers, and primary care providers convened to evaluate current evidence related to the treatment of TE. Methods: The primary research team, composed of 13 individuals, completed a comprehensive literature review of TE treatment. Then an expert panel conducted 2 rounds of article review, assessing each article based on the Strength of Recommendation Taxonomy (SORT) criteria and formulating consensus statements based on this data. An expert panel of 20 clinicians then evaluated the statements utilizing a structured eDelphi consensus process. Results: A total of 18 consensus statements regarding treatment recommendations for TE were reviewed by the expert panel. Of these, 3 statements addressed acute TE, while 15 focused on chronic TE. The panel evaluated each statement through open forum discussion, followed by voting and modification using the eDelphi methodology. Ultimately, 16 statements reached consensus following 2 rounds of the eDelphi survey. Conclusion: The self-limiting nature of acute TE warrants patient education, but no specific therapies were found to improve outcomes compared with placebo. While there is a gap in quality research regarding chronic TE treatment, current evidence suggests that topical minoxidil, vitamin D supplementation, and platelet-rich plasma may provide benefit in chronic TE based on individual clinical judgement.